10-K: SS Innovations International Reports Increased Revenue, Faces Going Concern Uncertainty in 2024 10-K Filing

SS Innovations International's 2024 10-K filing reveals a significant revenue increase driven by surgical robotic system sales, but also highlights substantial doubt about the company's ability to continue as a going concern due to recurring losses and dependence on external funding.

Summary

• SS Innovations International, Inc. (SSII) reported its 10-K filing for the year ended December 31, 2024.
• The company is focused on transforming patient lives by democratizing access to advanced surgical robotics technologies.
• SSII designs, manufactures, and markets the SSi Mantra surgical robotic system.
• The SSi Mantra has been clinically validated for safety, efficacy, and effectiveness in over 80 different types of surgical procedures in India.
• As of December 31, 2024, SSII had installed 62 systems, with 58 in India and 4 overseas.
• The company introduced the new generation SSi Mantra 3 Surgical Robotic System in June 2024.
• SSII is pursuing regulatory approval in the U.S. via the Investigational Device Exemption (IDE) route and expects to start a U.S. IDE study in the third quarter of 2025.
• The company is also in discussions with an EU Notified Body for CE certification.
• Total revenue for 2024 was $20,649,528, compared to $5,875,314 in 2023.
• The net loss for 2024 was $19,151,197, compared to a net loss of $20,878,292 in 2023.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and dependence on external funding.
• SSII plans to raise additional capital through private or public offerings in 2025.
• The company had shareholders' equity of $13,457,103 and a working capital surplus of $6,086,069 as of December 31, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's positive revenue growth and technological advancements, the going concern warning and internal control weaknesses raise significant concerns. The company's future depends heavily on securing additional funding and addressing its financial stability.

Positives

• Significant revenue growth in 2024 compared to 2023, indicating increasing market traction.
• Successful installation of SSi Mantra systems in multiple locations, both in India and overseas.
• Progress in regulatory approvals, including discussions with the FDA and an EU Notified Body.
• Decrease in net loss from 2023 to 2024.
• Successful completion of telesurgery and robotic cardiac telesurgery procedures.
• Expansion into Central and South American markets with the installation of the first SSi Mantra system in Ecuador.

Negatives

• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and dependence on external funding.
• Material weaknesses in internal control over financial reporting were identified.
• The company has a significant accumulated deficit of $43,662,547 as of December 31, 2024.
• The trading market for the company's common stock is sporadic and extremely limited.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• Failure to obtain regulatory approvals in the U.S. and EU could limit market access.
• Competition from established players in the surgical robotics market poses a significant challenge.
• The company's reliance on a limited number of suppliers for certain components could disrupt manufacturing.
• A legal proceeding involving an ex-shareholder of Otto Pvt Ltd. could have an unfavorable outcome.
• The company's disclosure controls and procedures were not effective as of December 31, 2024, due to material weaknesses in internal control over financial reporting.

Future Outlook

The company plans to focus on underserved markets, continue developing and enhancing its technology, and enter into evaluation, familiarization, and training agreements with major medical facilities. SSII expects to start its U.S. IDE study in the third quarter of 2025, subject to FDA and IRB approvals, and is also in discussions for CE certification in the EU. The company plans to raise additional capital through further private or public offerings in 2025.

Management Comments

• The document does not contain direct quotes, but it implies management's belief in the potential of the SSi Mantra to penetrate the Indian market and other underserved markets due to its advanced technology, lower cost, and ease of training.
• Management is focused on improving the design and technological capabilities of its existing SSi Mantra system and further expanding its product offerings.

Industry Context

The announcement aligns with the broader trend of increasing adoption of minimally invasive surgical robotics, particularly in emerging markets. The company aims to address the unmet need for affordable and accessible surgical robotic systems, competing with established players like Intuitive Surgical and others. The focus on telesurgery and remote proctoring also reflects the growing interest in leveraging technology to expand access to specialized surgical expertise.

Comparison to Industry Standards

• The global surgical robotics market is projected to reach US$23.7 billion by 2029, growing at a CAGR of 16.5%.
• Intuitive Surgical, Inc. is a major competitor in the surgical robotics market.
• SSII's strategy focuses on underserved markets like India, where robotic surgery penetration is low compared to developed countries.
• The company's cost-effective SSi Mantra system aims to disrupt the market by offering an affordable alternative to existing systems.
• SSII's development of telesurgery capabilities aligns with the industry's trend toward remote surgical assistance and training.
• The company's focus on a wide range of surgical procedures, including cardiac, thoracic, and urological surgeries, positions it to compete in various medical specialties.

Corporate Governance

Legal Proceedings

• In April 2024, an ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds approximately a 9% interest in Otto.
• The Bahamian court has issued an interim order to maintain the status quo with respect to the Otto shares and SSI-India's assets during the pendency of the litigation.
• Dr. Srivastava has agreed to fully indemnify the Company for any claims, damages, and costs incurred in connection with this litigation.

Related Party Transactions

• The company has engaged in several transactions with related parties, including Sushruta Pvt Ltd., Dr. Sudhir Srivastava, and other affiliates.
• These transactions include proceeds from notes issued, interest expense on notes, conversion of notes into common stock, and consultancy charges.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern status and the potential for dilution from future capital raises.
• Employees may be affected by the company's financial instability and potential limitations on expansion plans.
• Customers (hospitals and surgeons) may be concerned about the long-term viability of the company and its ability to provide ongoing support and maintenance for the SSi Mantra system.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• Pursue regulatory approval in the U.S. via the IDE route and start a U.S. IDE study in the third quarter of 2025.
• Continue discussions with an EU Notified Body for CE certification.
• Raise additional capital through private or public offerings in 2025.
• Address and remediate material weaknesses in internal control over financial reporting.
• Expand in-house manufacturing capacity to meet anticipated increases in demand and reduce reliance on third-party suppliers.

Key Dates

Keywords

surgical robotics, SSi Mantra, revenue, net loss, going concern, regulatory approval, internal control, tele-surgery, robotic surgery, SS Innovations, 10-K filing